001     143001
005     20240229112539.0
024 7 _ |a 10.1016/j.cgh.2019.01.014
|2 doi
024 7 _ |a pmid:30659991
|2 pmid
024 7 _ |a 1542-3565
|2 ISSN
024 7 _ |a 1542-7714
|2 ISSN
024 7 _ |a altmetric:65386563
|2 altmetric
037 _ _ |a DKFZ-2019-00626
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Ran, Tao
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Cost-effectiveness of Colorectal Cancer Screening Strategies-a Systematic Review.
260 _ _ |a New York, NY
|c 2019
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1567430293_12232
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Widespread screening for colorectal cancer (CRC) has reduced its incidence and mortality. Previous studies investigated the economic effects of CRC screening. We performed a systematic review to provide up to date evidence of the cost effectiveness of CRC screening strategies by answering 3 research questions.We searched PubMed, NHS EED, SSCI, EconLit, and 3 supplemental databases for original articles published in English from January 2010 through December 2017. All monetary values were converted to United States (US) dollars (year 2016). For all research questions, we extracted, or calculated (if necessary), per-person costs and life years (LY) and/or quality-adjusted LYs (QALY), as well as the incremental costs per LY gained or QALY gained compared to the baseline strategy. A cost-saving strategy is defined as one that was less costly and equally or more effective than the baseline strategy. Net monetary benefit approach was used to answer research question 2.Our review comprised 33 studies (17 from Europe, 11 from North America, 4 from Asia, and 1 from Australia). Annual and biennial guaiac-based fecal occult blood tests, annual and biennial fecal immunochemical tests, colonoscopy every 10 years, and flexible sigmoidoscopy every 5 years were cost-effective (even cost saving in most US models) compared with no screening. Additionally, colonoscopy every 10 years was less costly and/or more effective than other common strategies in the US. Newer strategies such as computed tomographic colonography, every 5 or 10 years, were cost-effective compared to no screening.In an updated review, we found that common CRC screening strategies and computed tomographic colonography continued to be cost-effective compared to no screening. There were discrepancies among studies from different regions, which could be associated with the model types or model assumptions.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Cheng, Chih-Yuan
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Misselwitz, Benjamin
|b 2
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 3
|u dkfz
700 1 _ |a Ubels, Jasper
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Schlander, Michael
|0 P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf
|b 5
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.cgh.2019.01.014
|g p. S1542356519300345
|0 PERI:(DE-600)2102638-5
|n 10
|p 1969-1981.e15
|t Clinical gastroenterology and hepatology
|v 17
|y 2019
|x 1542-3565
909 C O |p VDB
|o oai:inrepo02.dkfz.de:143001
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN GASTROENTEROL H : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CLIN GASTROENTEROL H : 2017
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l Klinische Epidemiologie und Alternsforschung
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)C100-20160331
|k C100
|l Gesundheitsökonomie
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)C100-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21